Inquiry Basket
Loading ......
Lecanemab is a humanized immunoglobulin gamma one (IgG1) monoclonal antibody that selectively targets soluble amyloid-beta protofibrils, a key pathological species implicated in the progression of Alzheimer's disease. Developed as a disease-modifying therapy, Lecanemab has demonstrated clinical efficacy in slowing cognitive decline in patients with early Alzheimer's disease, leading to regulatory approval in multiple countries. The mechanism of action involves binding to aggregated forms of amyloid-beta, promoting their clearance from the brain and reducing the accumulation of toxic plaques that are hallmarks of Alzheimer's pathology. The clinical success of Lecanemab has generated substantial demand for reliable bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic drug monitoring. Accurate quantification of Lecanemab concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response, optimizing dosing regimens, and ensuring patient safety. Additionally, detection of anti-Lecanemab antibodies is critical for evaluating the immunogenicity profile of this therapeutic antibody, as treatment-emergent anti-drug antibodies can alter pharmacokinetics, reduce efficacy, and potentially trigger adverse events.
Figure 1.High-Quality Reagents for Therapeutic Antibody Monitoring.
Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. The pathological hallmarks of Alzheimer's disease include extracellular amyloid-beta plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, neuronal loss, and synaptic dysfunction. Among these features, amyloid-beta aggregation is widely considered an initiating event in the disease cascade, triggering downstream pathological processes that ultimately lead to neurodegeneration. Amyloid-beta is produced through the sequential proteolytic cleavage of amyloid precursor protein by beta-secretase and gamma-secretase. This process generates amyloid-beta peptides of varying lengths, with amyloid-beta forty-two being particularly prone to aggregation and neurotoxicity. Soluble oligomeric and protofibrillar forms of amyloid-beta are now recognized as the most toxic species, disrupting synaptic function and triggering inflammatory responses before visible plaque deposition occurs.
Lecanemab is a humanized monoclonal antibody that exhibits high selectivity for soluble amyloid-beta protofibrils, a conformational intermediate between monomeric and fibrillar forms of amyloid-beta. Unlike other amyloid-targeting antibodies that primarily recognize monomers or insoluble fibrils, Lecanemab binds preferentially to protofibrils, which are believed to represent the most neurotoxic species. Upon binding to amyloid-beta protofibrils, Lecanemab facilitates their clearance through multiple mechanisms. The primary mechanism involves Fc-mediated microglial phagocytosis, where the antibody's Fc region engages Fc receptors on microglial cells, triggering internalization and degradation of the antibody-protofibril complexes. Additionally, Lecanemab may promote disaggregation of protofibrils and enhance central nervous system efflux of amyloid-beta across the blood-brain barrier. Clinical trials have demonstrated that Lecanemab reduces amyloid-beta plaque burden in the brain and slows cognitive decline in patients with early Alzheimer's disease.
| Pharmacokinetic Assessment | Immunogenicity Assessment | Therapeutic Drug Monitoring |
| Pharmacokinetic characterization describes the absorption, distribution, metabolism, and elimination of a therapeutic antibody. For Lecanemab, reliable quantification of drug concentrations in serum or plasma is essential for understanding the relationship between dose and exposure, evaluating the impact of patient characteristics on drug levels, and supporting dosing regimen optimization. Pharmacokinetic data from clinical trials inform product labeling and guide clinical use. | All biotherapeutic products have the potential to elicit immune responses resulting in the production of anti-drug antibodies. These anti-drug antibodies can have clinically significant consequences including altered pharmacokinetics, reduced efficacy, and infusion-related reactions. In rare cases, anti-drug antibodies may cross-react with endogenous proteins or neutralize essential factors, leading to serious adverse events. | Therapeutic drug monitoring involves measuring drug concentrations in individual patients to guide dosing decisions. For Lecanemab, therapeutic drug monitoring may be valuable in cases where patients experience suboptimal clinical responses or suspected adverse events related to drug exposure. Quantification of free drug levels can help clinicians assess whether therapeutic concentrations are achieved and maintained throughout the dosing interval. |
The Anti-Lecanemab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Lecanemab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
The Mouse Free Lecanemab ELISA Kit is specifically designed for the quantification of free Lecanemab concentrations in mouse serum, plasma, or other biological matrices. This kit is optimized for preclinical pharmacokinetic studies supporting the development of Lecanemab and related therapeutic antibodies.
Lecanemab represents a breakthrough in the treatment of Alzheimer's disease, offering the first disease-modifying therapy with clear evidence of clinical benefit. The successful development and clinical use of this therapeutic antibody depend critically on robust bioanalytical methods for pharmacokinetic assessment and immunogenicity monitoring. The Anti-Lecanemab ELISA Kit provides a sensitive, specific, and reproducible solution for detecting anti-drug antibodies in human biological samples, supporting immunogenicity assessment in clinical trials and post-marketing surveillance. The Mouse Free Lecanemab ELISA Kit enables accurate quantification of free drug concentrations in mouse biological matrices, facilitating preclinical pharmacokinetic studies that inform dose selection and clinical development. Together, these kits provide a comprehensive toolkit for the bioanalytical characterization of Lecanemab across all stages of development and clinical use. As the therapeutic landscape for Alzheimer's disease continues to evolve, reliable ELISA-based methods will remain essential for optimizing the use of Lecanemab and related antibodies in clinical practice.
<| Cat. No. | Product Name | Species Reactivity | Application | |
| DEIA-JY25019 | Free Lecanemab ELISA Kit | Human | This kit is designed for the quantitative detection of Lecanemab in serum and plasma using ELISA methodology. For research use only (RUO). Not for diagnostic procedures. | Inquiry |
| DEIA-JY25019M | Mouse Free Lecanemab ELISA Kit | Mouse | This kit is designed for the quantitative detection of Lecanemab in serum and plasma using ELISA methodology. For research use only (RUO). Not for diagnostic procedures. | Inquiry |
| DEIA-JY25039 | Total Lecanemab ELISA Kit | Human | This kit is designed for the quantitative detection of Lecanemab in serum and plasma using ELISA methodology. For research use only (RUO). Not for diagnostic procedures. | Inquiry |
Loading ......
